Product
Laronidase
Aliases
Aldurazyme, Recombinant human alpha L iduronidase
Name
ALDURAZYME
INN Name
laronidase
FDA Approved
Yes
4 clinical trials
1 organization
6 indications
1 document
Indication
Mucopolysaccharidosis Type IIndication
Hurler syndromeIndication
Mucopolysaccharidosis type IIndication
ScheieIndication
Mucopolysaccharidosis Type 1Indication
Hematopoietic Cell TransplantationClinical trial
A Multicenter, Multinational, Open-Label Study of the Effects of Aldurazyme® (Laronidase) Treatment on Lactation in Women With Mucopolysaccharidosis I (MPS I) and Their Breastfed InfantsStatus: Terminated, Estimated PCD: 2022-12-21
Clinical trial
A Phase III, Single Arm, Cross-over, Multicenter Clinical Trial to Compare Efficacy and Safety of P046 (Laronidase; CinnaGen) Versus Laronidase (Aldurazyme®; Genzyme, BioMarin) in Patients With Mucopolysaccharidosis Type I (MPS I)"Status: Completed, Estimated PCD: 2023-08-12
Clinical trial
A Phase 4, Single-arm, Open-label Safety and Efficacy Study of Aldurazyme® (Laronidase) as Enzyme Replacement Therapy in Participants With Mucopolysaccharidosis I (MPS I) in ChinaStatus: Completed, Estimated PCD: 2023-07-26
Clinical trial
Evaluation of Intravenous Laronidase Pharmacokinetics Before and After Hematopoietic Cell Transplantation in Patients With Mucopolysaccharidosis Type IH.Status: Recruiting, Estimated PCD: 2024-10-01
Document
DailyMed Label: ALDURAZYMEOrganization
Genzyme Corporation